H. Fujita et al., Optimum treatment strategy for superficial esophageal cancer: Endoscopic mucosal resection versus radical esophagectomy, WORLD J SUR, 25(4), 2001, pp. 424-431
This study was designed to determine the optimum treatment for a superficia
l esophageal cancer involving the mucosal or suhmucosal layer of the esopha
gus, The subjects were 150 patients with a superficial esophageal cancer wh
o underwent endoscopic mucosal resection (EMR) or esophagectomy in Kurume U
niversity Hospital from 1981 to 1997, Tile mortality and morbidity rates, s
urvival rate, and recurrence rate were retrospectively compared for (1) 35
patients who underwent EMR and 37 patients who underwent esophagectomy for
a mucosal esophageal cancer and (2) 45 patients who underwent extended radi
cal esophagectomy and 33 patients who underwent less radical esophagectomy
for a submucosal esophageal cancer. Among the 72 patients with a mucosal ca
ncer, lymph node metastasis/recurrence was observed in only one (1%); where
as of 78 patients with a suhmucosal cancer it was observed in 30(38%). Amon
g patients with a mucosal cancer the mortality and morbidity rates after EM
R were lower than for those after esophagectomy. The survival rate after EM
R was the same as that after esophagectomy. No recurrence was observed afte
r either treatment modality. Among the patients with a submucosal cancer, t
he survival rate was higher and the recurrence rate lower after extended ra
dical esophagectomy; than after less radical esophagectomy the mortality an
d morbidity rates after extended radical esophagectomy were the same as tho
se after less radical esophagectomy. Multivariate analysis demonstrated tha
t the treatment modality (EMR versus esophagectomy) did not influence the s
urvival of patients with a mucosal esophageal cancer, whereas it strongly i
nfluenced the survival of patients with a suhmucosal esophageal cancer, We
concluded that EMR was the mainstay; of treatment for a mucosal esophageal
cancer, and extended radical esophagectomy was the mainstay of treatment fo
r a submucosal esophageal cancer.